WhaleCreep

Avidity Partners Management LP 13F holdings, Q4 2022

Hedge fundSEC filingsCompare with another fundHoldings as of 2022-12-31, filed 2023-02-14

Avidity Partners Management LP disclosed 84 US equity positions worth $4.3bn in its Q4 2022 13F filing. Its largest position is ARGX at 5.5% of the reported book, followed by UTHR and NBIX. Versus Q3 2022 it opened 18 new positions, added to 30, reduced 18 and exited 30.

$4.3bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
84
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
5.5%
Largest position
The largest single position as a share of the reported equity book.
42.1%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
37
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q3 2022: 18 new, 30 added, 18 reduced, 30 exited

50 of 84
ARGX ARGENX SEHealthcare5.5%$237m625,000+27%added
UTHR UNITED THERAPEUTICS CORP DELHealthcare5.1%$218m785,500−19%reduced
NBIX NEUROCRINE BIOSCIENCES INCHealthcare5.0%$213m1.78m−4.1%reduced
AKROEUR AKERO THERAPEUTICS INC–4.9%$210m3.83m+23%added
PRTA PROTHENA CORP PLCHealthcare4.2%$178m2.95m+50%added
ARVN ARVINAS INCHealthcare4.0%$169m4.95m+14%added
BSX BOSTON SCIENTIFIC CORPHealthcare3.5%$151m3.26m+28%added
SNDX SYNDAX PHARMACEUTICALS INCHealthcare3.5%$149m5.86m+4.9%added
RARE ULTRAGENYX PHARMACEUTICAL INHealthcare3.2%$139m2.99m+46%added
SRPT SAREPTA THERAPEUTICS INCHealthcare3.2%$137m1.05m+11%added
MDGL MADRIGAL PHARMACEUTICALS INCHealthcare2.9%$125m430,000–new
UHS UNIVERSAL HLTH SVCS INCHealthcare2.7%$116m825,600–new
JAZZ JAZZ PHARMACEUTICALS PLCHealthcare2.7%$116m727,541+129%added
ZNTL ZENTALIS PHARMACEUTICALS INCHealthcare2.4%$104m5.15m+22%added
ACHC ACADIA HEALTHCARE COMPANY INHealthcare2.2%$95.9m1.17m−16%reduced
SGRY SURGERY PARTNERS INCHealthcare2.0%$86.7m3.11m+1063%added
DXCM DEXCOM INCHealthcare2.0%$85.7m756,800+62%added
AZN ASTRAZENECA PLCHealthcare1.9%$81.4m1.20m+113%added
LLY ELI LILLY & COHealthcare1.9%$79.4m217,000−78%reduced
PCVX VAXCYTE INCHealthcare1.8%$77.5m1.62m+157%added
RNAGBP AVIDITY BIOSCIENCES INC–1.7%$72.7m3.27m+26%added
NTRA NATERA INCHealthcare1.7%$72.3m1.80m+3.7%added
IDYA IDEAYA BIOSCIENCES INCHealthcare1.6%$69.5m3.82m+2.9%added
IMCR IMMUNOCORE HLDGS PLCHealthcare1.5%$65.9m1.15m−44%reduced
ALT ALTIMMUNE INCHealthcare1.5%$65.6m3.99m+49%added
RVMD REVOLUTION MEDICINES INCHealthcare1.4%$59.0m2.48m+6.6%added
KRTX KARUNA THERAPEUTICS INC–1.4%$58.8m299,000−31%reduced
ARWR ARROWHEAD PHARMACEUTICALS INHealthcare1.3%$55.8m1.38m+9.5%added
AXSM AXSOME THERAPEUTICS INC.Healthcare1.2%$51.7m670,000−56%reduced
VRTX VERTEX PHARMACEUTICALS INCHealthcare1.2%$49.7m172,000−66%reduced
LEGN LEGEND BIOTECH CORPHealthcare1.1%$48.4m970,000–new
KEZAR LIFE SCIENCES INC no ticker–1.1%$47.7m6.78m+25%added
PLRX PLIANT THERAPEUTICS INCHealthcare1.0%$43.3m2.24m+13%added
VTYXUSD VENTYX BIOSCIENCES INC–1.0%$42.1m1.28m–new
ICLR ICON PLCHealthcare1.0%$41.8m215,000–new
DGX QUEST DIAGNOSTICS INCHealthcare0.9%$40.4m258,000–new
BIO BIO RAD LABS INCHealthcare0.9%$38.8m92,200−36%reduced
BLU BELLUS HEALTH INC NEW–0.9%$37.8m4.60m+5.8%added
THC TENET HEALTHCARE CORPHealthcare0.8%$35.0m717,300–new
KPTI KARYOPHARM THERAPEUTICS INCHealthcare0.8%$32.8m9.63m–new
BNTX BIONTECH SEHealthcare0.8%$32.4m215,400–new
VERVE THERAPEUTICS INC no ticker–0.7%$30.3m1.56m+50%added
RCKT ROCKET PHARMACEUTICALS INCHealthcare0.7%$29.9m1.53m–new
ITCIEUR INTRA-CELLULAR THERAPIES INC–0.6%$26.7m504,000−64%reduced
ARQT ARCUTIS BIOTHERAPEUTICS INCHealthcare0.6%$26.0m1.75m+121%added
PROMETHEUS BIOSCIENCES INC no ticker–0.5%$22.4m204,000–new
NTLA INTELLIA THERAPEUTICS INCHealthcare0.5%$22.3m638,200−36%reduced
VIR VIR BIOTECHNOLOGY INCHealthcare0.5%$21.5m850,000–new
PHAT PHATHOM PHARMACEUTICALS INCHealthcare0.5%$21.3m1.90m−0.4%held
BHVN BIOHAVEN LTDHealthcare0.5%$20.7m1.49m–new

Exited since Q3 2022

30 rows
BIIB BIOGEN INC3.5%$160m
XBI SPDR SERIES TRUST2.6%$117m
HUM HUMANA INC2.2%$103m
ELV ELEVANCE HEALTH INC2.1%$94.3m
HORIZON THERAPEUTICS PUB L no ticker2.0%$91.7m
AVTR AVANTOR INC1.9%$88.6m
CTLTEUR CATALENT INC1.5%$68.0m
SGENUSD SEAGEN INC1.3%$61.0m
ALNY ALNYLAM PHARMACEUTICALS INC1.3%$57.7m
APLSUSD APELLIS PHARMACEUTICALS INC1.3%$57.6m
SYK STRYKER CORPORATION0.8%$37.4m
CNC CENTENE CORP DEL0.7%$33.6m
NGMUSD NGM BIOPHARMACEUTICALS INC0.5%$23.5m
COGT COGENT BIOSCIENCES INC0.4%$20.3m
NKTX NKARTA INC0.4%$18.6m
ONC BEIGENE LTD0.4%$17.8m
SIBN SI-BONE INC0.4%$17.4m
GOSS GOSSAMER BIO INC0.4%$17.4m
ATEC ALPHATEC HLDGS INC0.3%$15.0m
IOVA IOVANCE BIOTHERAPEUTICS INC0.3%$13.2m
TMDX TRANSMEDICS GROUP INC0.3%$12.5m
STOK STOKE THERAPEUTICS INC0.2%$11.4m
SPNEUSD SEASPINE HLDGS CORP0.2%$11.4m
ERAS ERASCA INC0.2%$7.7m
BCLS ACQUISITION CORP no ticker0.1%$5.0m
TNGX TANGO THERAPEUTICS INC0.06%$2.9m
ONCOSEC MED INC no ticker0.03%$1.4m
WGS GENEDX HOLDINGS CORP0.02%$834k
PHASEUR PHASEBIO PHARMACEUTICALS INC0.02%$768k
SCIENCE 37 HOLDINGS INC no ticker0.02%$692k

Sector mix

  • Healthcare84.1%
  • Unclassified15.9%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters